Saturday 17 October 2026
Export NNVC’s income statement to Excel — free account
NanoViricides, Inc.
NNVC Healthcare Biotechnology
In the quarter to June 2026, EPS grew 24.1% and free cash flow fell 23.9%, each against the same quarter a year earlier.
1.38
0.01
+0.73%
Follow NNVC
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | 17.40 | 4.00 | 1.27 | 2.25 | 2.91 | 1.04 | 1.00 | 1.01 | 0.94 | 0.85 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | 32.80 | 21.60 | 13.60 | 19.20 | 8.71 | 3.93 | 2.00 | 3.59 | 2.23 | 1.93 | |||||
| People | |||||||||||||||
| People | Employees | 7 | 7 | 17 | 17 | 17 | 17 | 7 | 7 | 7 | 7 | ||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | (10) | (9) | (8) | (13) | (9) | (8) | (9) | (8) | (9) | (8) | |||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | (10) | (9) | (8) | (13) | (9) | (8) | (9) | (8) | (9) | (8) | |||||
| Depreciation | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | (3.40) | (2.60) | (2.40) | (2.39) | (0.81) | (0.70) | (0.74) | (0.70) | (0.63) | (0.41) | |||||
| Cash flow | (2.63) | (2.40) | (1.89) | (1.19) | (0.75) | (0.51) | (0.49) | (0.53) | (0.56) | (0.38) | |||||
| Capex | (0.05) | (0.07) | (0.02) | 0.00 | (0.02) | (0.03) | (0.01) | (0.01) | 0.00 | 0.00 | |||||
| Free cash flow | (2.68) | (2.47) | (1.92) | (1.19) | (0.78) | (0.54) | (0.50) | (0.55) | (0.56) | (0.39) | |||||
| Book value | 6.76 | 5.44 | 2.95 | 3.87 | 2.74 | 2.00 | 1.28 | 0.97 | 0.50 | 0.43 | |||||
| Shares, m | 3 | 3 | 4 | 6 | 11 | 12 | 12 | 12 | 15 | 20 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | (8) | (8) | (7) | (7) | (8) | (6) | (6) | (6) | (8) | (8) | ||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
| Free cash flow | (8) | (8) | (7) | (7) | (8) | (6) | (6) | (6) | (9) | (8) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | 11 | 6 | 0 | 12 | 20 | 14 | 8 | 4 | 0 | 2 | ||||
| Total debt | 4 | — | — | 0 | 0 | 0 | — | — | — | — | |||||
| Net debt | (11) | (7) | (3) | (14) | (20) | (14) | (8) | (5) | (2) | (3) | |||||
| Shareholders’ equity | 20 | 18 | 11 | 22 | 30 | 23 | 15 | 11 | 8 | 9 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | (32.39) | (37.60) | (52.66) | (71.98) | (32.57) | (30.16) | (42.52) | (55.81) | (87.47) | (87.91) | ||||
| ROIC | (65.37) | (55.07) | (67.27) | (61.61) | (57.59) | (55.66) | (83.23) | (79.84) | (100.60) | (88.16) | |||||
| ROE | (47.53) | (45.10) | (59.62) | (83.11) | (34.15) | (30.60) | (45.27) | (63.00) | (99.75) | (101.46) | |||||
Negative figures in brackets.
Fundamentals updated 30 Sep 2026
Charts ten years each
NanoViricides, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| FLNA Cassava Sciences, Inc. | $36.8M | — (loss-making) | — | +1,328.04% (above 0%: growing) | n/m | +21.65% (above 0%: growing) | 0.00% | 0.00% | Compare |
| LITS Lite Strategy, Inc. | $36.3M | — (loss-making) | — (loss-making) | +647.96% (above 0%: growing) | n/m | +179.28% (above 0%: growing) | 0.00% | 0.00% | Compare |
| EDSA Edesa Biotech, Inc. | $36.1M | — (loss-making) | — (loss-making) | −99.88% (below 0%: shrinking) | n/m | −81.24% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NNVC NanoViricides, Inc. | $35.0M | — (loss-making) | — | — | n/m | −23.94% (below 0%: shrinking) | 0.00% | 0.00% | |
| LIANY LianBio Sponsored ADR | $34.2M | 0.0× | — | — | n/m | +1,107.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CRVO CervoMed Inc. | $34.0M | — (loss-making) | — (loss-making) | −99.60% (below 0%: shrinking) | n/m | −6.20% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| IRLA Quince Therapeutics, Inc. | $33.8M | — (loss-making) | — | — | n/m | −63.65% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ALGS Aligos Therapeutics, Inc. | $33.7M | — (loss-making) | — (loss-making) | +2,778.55% (above 0%: growing) | n/m | −59.81% (below 0%: shrinking) | 100.00% | (6.80%) | Compare |
| ATNM Actinium Pharmaceuticals, Inc. | $33.3M | 3.1× | — (loss-making) | +77,677.78% (above 0%: growing) | n/m | −4.91% (below 0%: shrinking) | 100.00% | 78.76% | Compare |
| Median of peers | $34.1M | — | — | +988.00% | — | −5.55% | 0.00% | 0.00% |
NanoViricides, Inc. (NNVC) key facts
- NanoViricides, Inc. (NNVC) is a Biotechnology company in the Healthcare sector, listed on NYSE American.
- As of October 16, 2026, NNVC traded at $1.38, a market capitalization of $35.0 million.
- Return on equity was −101.5% and debt-to-equity 0.00.